Can a single infusion protect kidneys during cancer treatment?
NCT ID NCT04745910
First seen Nov 10, 2025 · Last updated May 08, 2026 · Updated 21 times
Summary
This study tested the drug pegloticase in 10 cancer patients with high uric acid levels caused by tumor lysis syndrome, a complication where dying cancer cells release substances that can damage the kidneys. The goal was to see if pegloticase could quickly lower uric acid and protect kidney function. Results will show how well the drug works within 24 hours and how long it takes for uric acid to drop to safe levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.